These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37085716)

  • 1. Infographic: Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months: the VICI study.
    Yusuf IH; Henein C; Sivaprasad S
    Eye (Lond); 2024 Aug; 38(Suppl 2):33-34. PubMed ID: 37085716
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
    Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC;
    Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
    Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
    Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OCT-A in chronic central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study.
    Uzun S; Uzun F; Ercal O
    Eur J Ophthalmol; 2024 May; 34(3):NP131. PubMed ID: 37899582
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
    Yang D; Eliott D
    Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
    Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
    Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone in patients with chronic recurring central serous chorioretinopathy.
    Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O
    Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
    Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
    Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
    Bousquet E; Zhao M; Daruich A; Behar-Cohen F
    Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone for treatment of chronic central serous chorioretinopathy.
    Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD
    Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
    Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
    J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone for chronic central serous chorioretinopathy.
    Stanescu-Segall D; Touhami S; Bodaghi B; LeHoang P
    Lancet; 2020 Nov; 396(10262):1556-1557. PubMed ID: 33189169
    [No Abstract]   [Full Text] [Related]  

  • 15. Eplerenone for chronic central serous chorioretinopathy.
    Sacconi R; Borrelli E; Querques G
    Lancet; 2020 Nov; 396(10262):1556. PubMed ID: 33189168
    [No Abstract]   [Full Text] [Related]  

  • 16. Eplerenone for chronic central serous chorioretinopathy - Authors' reply.
    Lotery A; O'Connell A; Harris RA; Sivaprasad S; Reeves BC
    Lancet; 2020 Nov; 396(10262):1557-1558. PubMed ID: 33189170
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
    Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
    Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'.
    Lotery A; Sivaprasad S; O'Connell A; Reeves B
    Eye (Lond); 2021 Dec; 35(12):3448. PubMed ID: 34089001
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to comment on: Optical coherence tomography angiography in central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study.
    Clemente L; Cennamo G; Montorio D; Fossataro F; Passaro ML; Costagliola C
    Eur J Ophthalmol; 2024 May; 34(3):NP132-NP133. PubMed ID: 37899584
    [No Abstract]   [Full Text] [Related]  

  • 20. Bullous central serous chorioretinopathy with retinal pigment epithelial macro rip treated with eplerenone monotherapy.
    Naharwal A; Samanta R; Jayaraj S; Agrawal A
    BMJ Case Rep; 2024 Aug; 17(8):. PubMed ID: 39214585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.